Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

Abstract Ras mutations (e.g., occur in K-Ras, N-Ras, and H-Ras) are one of the most desirable and promising drug targets in chemotherapy treatments for cancer. However, there are still no approved drugs directly targeting mutated Ras. In 2017, an artificial cyclic peptide, KRpep-2d, was discovered a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kotaro Sakamoto, Teruaki Masutani, Takatsugu Hirokawa
Format: article
Langue:EN
Publié: Nature Portfolio 2020
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/1169d92c6a314ea185bfdf3f8304635f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!